[{"id":"6dd064ce-a694-4785-a251-cdfbdd1c7abc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101839","created_at":"2021-01-18T15:16:55.418Z","updated_at":"2024-07-02T16:36:54.847Z","phase":"Phase 1","brief_title":"Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03101839","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD4785"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 01/08/2019","primary_completion_date":" 01/08/2019","study_txt":" Completion: 01/08/2019","study_completion_date":" 01/08/2019","last_update_posted":"2019-10-04"}]